Overall, KYA1797K effectively suppressed the formation and growth of tumor-derived organoids from CRC patients and overcame the insensitivity to cetuximab attributed to KRAS mutations by reducing the protein levels via degradation. This evidence concerns the gene KRAS and colorectal carcinoma.